RU2013142448A - Новые сульфонаминохинолиновые антагонисты гепсидина - Google Patents
Новые сульфонаминохинолиновые антагонисты гепсидина Download PDFInfo
- Publication number
- RU2013142448A RU2013142448A RU2013142448/04A RU2013142448A RU2013142448A RU 2013142448 A RU2013142448 A RU 2013142448A RU 2013142448/04 A RU2013142448/04 A RU 2013142448/04A RU 2013142448 A RU2013142448 A RU 2013142448A RU 2013142448 A RU2013142448 A RU 2013142448A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- compound
- group
- hydrogen atom
- anemia
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 37
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 19
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract 19
- 125000005415 substituted alkoxy group Chemical group 0.000 claims abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 9
- 125000003277 amino group Chemical group 0.000 claims abstract 7
- 125000002252 acyl group Chemical group 0.000 claims abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 6
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 4
- 125000004423 acyloxy group Chemical group 0.000 claims abstract 3
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 208000007502 anemia Diseases 0.000 claims 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000016286 Iron metabolism disease Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- BVRDQVRQVGRNHG-UHFFFAOYSA-N 2-morpholin-4-ylpyrimido[2,1-a]isoquinolin-4-one Chemical compound N1=C2C3=CC=CC=C3C=CN2C(=O)C=C1N1CCOCC1 BVRDQVRQVGRNHG-UHFFFAOYSA-N 0.000 claims 1
- 208000020459 Anaemia of malignant disease Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 0 *C(*)(*)c1cc(-c2c(C=O)ccc(Cl)c2)c(CC2CC2)c2c1cccn2 Chemical compound *C(*)(*)c1cc(-c2c(C=O)ccc(Cl)c2)c(CC2CC2)c2c1cccn2 0.000 description 5
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N CCCN(C)C Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- CAENGPHEFXNJEG-UHFFFAOYSA-N Cc(c1c2nccc1)cc(-c(cccc1)c1S=O)c2NC=O Chemical compound Cc(c1c2nccc1)cc(-c(cccc1)c1S=O)c2NC=O CAENGPHEFXNJEG-UHFFFAOYSA-N 0.000 description 1
- FRISYCOTWLRENK-UHFFFAOYSA-N N#Cc1cc(-c2c(C=O)ccc(Cl)c2)c(CC2CC2)c2c1cccn2 Chemical compound N#Cc1cc(-c2c(C=O)ccc(Cl)c2)c(CC2CC2)c2c1cccn2 FRISYCOTWLRENK-UHFFFAOYSA-N 0.000 description 1
- LASOZEBRPGWOSN-UHFFFAOYSA-N O=C(c(cc1)cc(-c(cc(c2c3nccc2)Cl)c3N2)c1S2=O)N1CCOCC1 Chemical compound O=C(c(cc1)cc(-c(cc(c2c3nccc2)Cl)c3N2)c1S2=O)N1CCOCC1 LASOZEBRPGWOSN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11155103 | 2011-02-18 | ||
| EP11155103.2 | 2011-02-18 | ||
| US201161473223P | 2011-04-08 | 2011-04-08 | |
| US61/473,223 | 2011-04-08 | ||
| US13/364,566 | 2012-02-02 | ||
| US13/364,566 US20120214803A1 (en) | 2011-02-18 | 2012-02-02 | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| PCT/EP2012/052694 WO2012110603A1 (en) | 2011-02-18 | 2012-02-16 | Novel sulfonaminoquinoline hepcidin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013142448A true RU2013142448A (ru) | 2015-03-27 |
Family
ID=44201356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013142448/04A RU2013142448A (ru) | 2011-02-18 | 2012-02-16 | Новые сульфонаминохинолиновые антагонисты гепсидина |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120214803A1 (enExample) |
| EP (1) | EP2675526B1 (enExample) |
| JP (1) | JP5948352B2 (enExample) |
| KR (1) | KR20140009396A (enExample) |
| CN (1) | CN103492028B (enExample) |
| AR (1) | AR085283A1 (enExample) |
| AU (1) | AU2012217021A1 (enExample) |
| BR (1) | BR112013020916A2 (enExample) |
| CA (1) | CA2826463A1 (enExample) |
| ES (1) | ES2623229T3 (enExample) |
| MX (1) | MX2013009522A (enExample) |
| RU (1) | RU2013142448A (enExample) |
| TW (1) | TW201302710A (enExample) |
| WO (1) | WO2012110603A1 (enExample) |
| ZA (1) | ZA201306005B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122534A2 (en) | 2011-03-10 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation |
| HK1217092A1 (zh) | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| CN105189462B (zh) | 2013-02-20 | 2017-11-10 | 卡拉制药公司 | 治疗性化合物和其用途 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| CA2902624C (en) | 2013-02-28 | 2021-05-18 | Takeda Pharmaceutical Company Limited | Method for producing sulfonyl chloride compound |
| MX363708B (es) | 2013-10-14 | 2019-03-29 | Eisai R&D Man Co Ltd | Compuestos de quinolina selectivamente sustituidos. |
| SG10201704327RA (en) | 2013-10-14 | 2017-06-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA2958142A1 (en) * | 2014-08-14 | 2016-02-18 | Rigel Pharmaceuticals, Inc. | Quinoline derivatives useful as ubiquitination inhibitors |
| CN105237476A (zh) * | 2015-10-31 | 2016-01-13 | 高大元 | 一种4-氯-8-氨基喹啉的合成方法 |
| MX2021006804A (es) * | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| RU2758686C2 (ru) | 2016-08-08 | 2021-11-01 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
| WO2018048746A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036336A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3728194B1 (en) * | 2017-12-20 | 2025-06-04 | Otago Innovation Limited | Quinoline sulfonamide compounds and their use as antibacterial agents |
| CN111253934B (zh) * | 2018-11-30 | 2023-06-16 | 中国科学院大连化学物理研究所 | 一种双光子荧光探针及其制备和应用 |
| CN110407721A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| IL297437A (en) | 2020-05-13 | 2022-12-01 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| KR20230146012A (ko) * | 2021-02-09 | 2023-10-18 | 셀진 코포레이션 | 연충 감염 및 질병의 치료를 위한 설폰아미드 및 이들의용도 |
| IT202100013244A1 (it) | 2021-05-21 | 2022-11-21 | Fond Telethon | MODULATORI DI PrPC E LORO USI |
| CN113292490B (zh) * | 2021-06-04 | 2022-05-10 | 石家庄学院 | 一种识别氯离子的荧光探针及其制备方法和用途 |
| CN113717080A (zh) * | 2021-10-09 | 2021-11-30 | 西安瑞联新材料股份有限公司 | 一种4-氯-2-氰基苯磺酰氯的合成方法 |
| WO2023064058A1 (en) * | 2021-10-12 | 2023-04-20 | Peloton Therapeutics Inc. | Tricyclic sultams and sulfamides as antitumor agents |
| CN120514715B (zh) * | 2025-07-25 | 2025-10-17 | 深圳国家感染性疾病临床医学研究中心 | 磺胺类化合物的应用、结核分枝杆菌抑制剂、药物组合物及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1025618C (zh) * | 1988-12-26 | 1994-08-10 | 日高弘义 | 异喹啉磺酰胺衍生物的制备方法 |
| US5627193A (en) | 1995-02-09 | 1997-05-06 | Mitsui Toatsu Chemicals, Inc. | Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds |
| US7166448B1 (en) | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| ES2693050T3 (es) | 2001-05-25 | 2018-12-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Uso de hepcidina para preparar un medicamento para tratar trastornos de la homeostasis del hierro |
| JP4638350B2 (ja) | 2002-11-19 | 2011-02-23 | ディーアールジー・インターナショナル，インコーポレイテッド | ヒトまたは動物の組織、血液もしくは体液中のヘプシジンの存在または量を検出する方法 |
| US8614204B2 (en) * | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| US7723063B2 (en) | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| CA2549477A1 (en) | 2005-06-29 | 2006-12-29 | The Regents Of The University Of California | Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| EP2066687A4 (en) | 2006-09-21 | 2010-12-08 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HAMP GENE |
| WO2008074068A1 (en) * | 2006-12-20 | 2008-06-26 | Prana Biotechnology Limited | Substituted quinoline derivatives as antiamyloidogeneic agents |
| TW201307390A (zh) | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| CL2008000666A1 (es) | 2007-03-07 | 2008-06-13 | Xenon Pharmaceuticals Inc | Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro. |
| AR065785A1 (es) | 2007-03-19 | 2009-07-01 | Xenon Pharmaceuticals Inc | Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| WO2008144011A1 (en) | 2007-05-16 | 2008-11-27 | Avalon Pharmaceuticals | Compounds and methods for treating or preventing autoimmune diseases |
| EP2068855A2 (en) | 2007-06-05 | 2009-06-17 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
| GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| WO2009044284A1 (en) | 2007-10-02 | 2009-04-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies specific for human hepcidin |
| JO2828B1 (en) | 2007-11-02 | 2014-09-15 | ايلي ليلي اند كومباني | Anti-Hepsidine antibodies and their uses |
| EA021938B1 (ru) * | 2008-05-01 | 2015-10-30 | Сертрис Фармасьютикалз, Инк. | Хинолины и их аналоги в качестве модуляторов сиртуина |
| WO2010051064A1 (en) | 2008-10-30 | 2010-05-06 | The Trustees Of Columbia University In The City Of New York | COMPOUNDS THAT INHIBIT NFκB ACTIVITY |
-
2012
- 2012-02-02 US US13/364,566 patent/US20120214803A1/en not_active Abandoned
- 2012-02-16 MX MX2013009522A patent/MX2013009522A/es not_active Application Discontinuation
- 2012-02-16 BR BR112013020916A patent/BR112013020916A2/pt not_active IP Right Cessation
- 2012-02-16 CN CN201280018909.9A patent/CN103492028B/zh not_active Expired - Fee Related
- 2012-02-16 WO PCT/EP2012/052694 patent/WO2012110603A1/en not_active Ceased
- 2012-02-16 KR KR1020137025002A patent/KR20140009396A/ko not_active Withdrawn
- 2012-02-16 EP EP12704090.5A patent/EP2675526B1/en not_active Not-in-force
- 2012-02-16 RU RU2013142448/04A patent/RU2013142448A/ru unknown
- 2012-02-16 CA CA2826463A patent/CA2826463A1/en not_active Abandoned
- 2012-02-16 JP JP2013553947A patent/JP5948352B2/ja not_active Expired - Fee Related
- 2012-02-16 ES ES12704090.5T patent/ES2623229T3/es active Active
- 2012-02-16 AU AU2012217021A patent/AU2012217021A1/en not_active Abandoned
- 2012-02-17 TW TW101105292A patent/TW201302710A/zh unknown
- 2012-02-17 AR ARP120100551A patent/AR085283A1/es not_active Application Discontinuation
-
2013
- 2013-08-08 ZA ZA2013/06005A patent/ZA201306005B/en unknown
-
2014
- 2014-06-20 US US14/310,254 patent/US9102688B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012110603A1 (en) | 2012-08-23 |
| CN103492028B (zh) | 2017-02-08 |
| ZA201306005B (en) | 2014-04-30 |
| JP5948352B2 (ja) | 2016-07-06 |
| KR20140009396A (ko) | 2014-01-22 |
| CN103492028A (zh) | 2014-01-01 |
| AU2012217021A1 (en) | 2013-08-22 |
| CA2826463A1 (en) | 2012-08-23 |
| US20140364424A1 (en) | 2014-12-11 |
| US20120214803A1 (en) | 2012-08-23 |
| TW201302710A (zh) | 2013-01-16 |
| JP2014508753A (ja) | 2014-04-10 |
| EP2675526A1 (en) | 2013-12-25 |
| MX2013009522A (es) | 2013-10-01 |
| BR112013020916A2 (pt) | 2016-10-04 |
| ES2623229T3 (es) | 2017-07-10 |
| AR085283A1 (es) | 2013-09-18 |
| EP2675526B1 (en) | 2017-02-01 |
| US9102688B2 (en) | 2015-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| JP2014508753A5 (enExample) | ||
| AR093532A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| RU2013152788A (ru) | Амидные соединения и их фармацевтическое применение | |
| JP2015501833A5 (enExample) | ||
| EA200870545A1 (ru) | Новые гетероциклические соединения | |
| JP2013519653A5 (enExample) | ||
| AR092045A1 (es) | Combinaciones farmaceuticas | |
| CA2769553A1 (en) | Novel pyrimidine and triazine hepcidin antagonists | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| JP2015504067A5 (enExample) | ||
| JP2010503688A5 (enExample) | ||
| JPWO2021081212A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| RU2009135621A (ru) | Хинолиновые производные для лечения воспалительных заболеваний | |
| RU2015106434A (ru) | Производные типа азаиндазола или диазаиндазола для лечения боли | |
| EA201390401A1 (ru) | ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ | |
| RU2009146376A (ru) | Способы применения антагонистов вазопрессина с антрациклиновыми химиотерапевтическими средствами для снижения кардиотоксичности и/или улучшения выживания | |
| JP2013540713A5 (enExample) | ||
| EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
| RU2013140169A (ru) | Противоопухолевое терапевтическое средство | |
| JP2016513696A5 (enExample) | ||
| AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
| JP2015512943A5 (enExample) |